Deoxynivalenol: rationale for development and application of a urinary biomarker.
about
Evaluation of insulin-like growth factor acid-labile subunit as a potential biomarker of effect for deoxynivalenol-induced proinflammatory cytokine expressionProteomic analysis of the effects of the immunomodulatory mycotoxin deoxynivalenol.Suppression of insulin-like growth factor acid-labile subunit expression--a novel mechanism for deoxynivalenol-induced growth retardationEvaluation of an oral subchronic exposure of deoxynivalenol on the composition of human gut microbiota in a model of human microbiota-associated ratsDeoxynivalenol-induced proinflammatory gene expression: mechanisms and pathological sequelae.Determination of Deoxynivalenol in the Urine of Pregnant Women in the UK.The Food Contaminant Deoxynivalenol Exacerbates the Genotoxicity of Gut Microbiota.The role of biomarkers in evaluating human health concerns from fungal contaminants in food.Characterisation of aflatoxin and deoxynivalenol exposure among pregnant Egyptian women.Deoxynivalenol Biomarkers in the Urine of UK Vegetarians.Advances in Mycotoxin Research: Public Health Perspectives.A comparison of deoxynivalenol intake and urinary deoxynivalenol in UK adults.Urine metabolite analysis as a function of deoxynivalenol exposure: an NMR-based metabolomics investigation.Simultaneous LC-MS/MS determination of aflatoxin M1, ochratoxin A, deoxynivalenol, de-epoxydeoxynivalenol, α and β-zearalenols and fumonisin B1 in urine as a multi-biomarker method to assess exposure to mycotoxins.Mycotoxin binder improves growth rate in piglets associated with reduction of toll-like receptor-4 and increase of tight junction protein gene expression in gut mucosa.Assessment of Urinary Deoxynivalenol Biomarkers in UK Children and Adolescents.Diagnosis of intoxications of piglets fed with Fusarium toxin-contaminated maize by the analysis of mycotoxin residues in serum, liquor and urine with LC-MS/MS.Annual variation of dietary deoxynivalenol exposure during years of different Fusarium prevalence: a pilot biomonitoring study.Humans significantly metabolize and excrete the mycotoxin deoxynivalenol and its modified form deoxynivalenol-3-glucoside within 24 hours.Comparison of single and multi-analyte methods based on LC-MS/MS for mycotoxin biomarker determination in human urine
P2860
Q33697732-924DC777-FFBA-4DA7-A302-66E4ECEC8E4FQ33861765-BDA74ADD-FB24-422B-9997-617C664CE595Q33988934-9E67EACC-C2BE-4689-8C5F-DF9A6FB45978Q35049126-2CCCA9F8-AE42-4EEF-A5BF-553AE9E356FAQ35155832-29B78E81-54E4-4FA0-AECE-C743449F292AQ37450350-67BFCB94-AC82-4405-BB8F-DC8F7482F74BQ37700056-9C1905AD-EDAD-44A2-A610-CD7D4145521EQ38014991-7DE4F041-F75B-49E5-96EC-8F66BF1EEACEQ39355569-4834A916-D31A-4FB7-A0AC-E3C78C010A36Q40149644-AAB00CE2-3392-4DFE-B93A-DE26F7F05D7AQ40324481-AF0B5183-AB2A-410D-A425-1D6919439921Q43007757-D02416E9-A77C-436C-BCEC-68D73A036716Q43219491-AEC738CF-4024-4146-870A-6CD1C1201107Q45206156-BC278DDF-531A-400C-8627-551E27DC089FQ46265212-7ABCDC91-F106-48B6-AC42-9DF78919F772Q47550024-0E05756B-B722-445A-981D-14A6B28E0F97Q51018559-A5E54990-CE73-474E-BDF1-0C561F7AE2A1Q51251897-236AB0C8-D472-4E65-B1BA-AB21226FF5C1Q52626721-FD3687A0-2826-478C-BDDF-432321EA8BD7Q56838884-844B08A9-CAC6-48CF-AEE9-767F7C0A44AE
P2860
Deoxynivalenol: rationale for development and application of a urinary biomarker.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Deoxynivalenol: rationale for development and application of a urinary biomarker.
@en
Deoxynivalenol: rationale for development and application of a urinary biomarker.
@en-gb
type
label
Deoxynivalenol: rationale for development and application of a urinary biomarker.
@en
Deoxynivalenol: rationale for development and application of a urinary biomarker.
@en-gb
prefLabel
Deoxynivalenol: rationale for development and application of a urinary biomarker.
@en
Deoxynivalenol: rationale for development and application of a urinary biomarker.
@en-gb
P2093
P2860
P1476
Deoxynivalenol: rationale for development and application of a urinary biomarker.
@en
P2093
Christopher P Wild
Joseph A Rothwell
Kay L M White
Paul C Turner
P2860
P304
P356
10.1080/02652030801895040
P577
2008-07-01T00:00:00Z